Using the same methodology, Peddie and colleagues have shown that this damage could only be found within the CD34+ bone marrow cell population from MDS patients (which includes the HSC population), but not in more differentiated CD34− cells, nor in healthy donor marrow cells [46]. This evidence concerns the gene CD34 and myelodysplastic syndrome.